Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers

Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers

Targeting anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase receptor initially identified as a potent oncogenic driver in anaplastic large-cell lymphoma (ALCL) in the form of nucleophosmin (NPM)-ALK fusion protein, using tyrosine kinase inhibitors has shown to be a promising therapeutic a...

Full description

Bibliographic Details
Main Author: Abdulraheem Alshareef
Format: Article
Language:English
Published: MDPI AG 2017-10-01
Series:Cancers
Subjects:
anaplastic lymphoma kinase
ALK-expressing cancers
cancer stem cells
crizotinib
clinical resistance
tyrosine kinases
tyrosine kinase inhibitors
Online Access:https://www.mdpi.com/2072-6694/9/11/148

Internet

https://www.mdpi.com/2072-6694/9/11/148

Similar Items